Zoetis Inc. (NYSE:ZTS) Shares Bought by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 115,989 shares of the company’s stock after buying an additional 4,771 shares during the period. Zoetis comprises approximately 1.9% of Franklin Street Advisors Inc. NC’s investment portfolio, making the stock its 20th biggest position. Franklin Street Advisors Inc. NC’s holdings in Zoetis were worth $22,893,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Evermay Wealth Management LLC lifted its position in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new stake in Zoetis during the first quarter worth approximately $26,000. VisionPoint Advisory Group LLC bought a new position in shares of Zoetis in the second quarter valued at approximately $29,000. Finally, Moisand Fitzgerald Tamayo LLC lifted its stake in shares of Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after buying an additional 96 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.4 %

Shares of ZTS opened at $169.12 on Friday. The stock has a 50 day simple moving average of $185.92 and a 200-day simple moving average of $182.24. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The stock has a market cap of $77.43 billion, a PE ratio of 33.36, a PEG ratio of 2.57 and a beta of 0.87. Zoetis Inc. has a 1 year low of $151.03 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the business posted $1.15 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Stifel Nicolaus raised their target price on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. Piper Sandler boosted their target price on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group raised their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $224.33.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 2,209 shares of company stock valued at $408,453 in the last three months. 0.12% of the stock is owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.